Non-alcoholic fatty liver disease and thrombocytopenia IV: its association with granulocytopenia

Rivera-Álvarez, Montserrat; Córdova-Ramírez, Alejandra Carmina; Elías-De-La-Cruz, Gilberto David; Murrieta-Álvarez, Iván; León-Peña, Andrés Aurelio; Cantero-Fortiz, Yahveth; Olivares-Gazca, Juan Carlos; Ruiz-Delgado, Guillermo José; Ruiz-Argüelles, Guillermo José.
Hematol., Transfus. Cell Ther. (Impr.) ; 44(4): 491-496, Oct.-dec. 2022. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1421533

Documentos relacionados

  1. 'Mistakes in managing non-alcoholic fatty liver disease and how to avoid them'.
  2. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH.
  3. Contribution of classification based on ferroptosis-related genes to the heterogeneity of MAFLD.
  4. Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease.
  5. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups.
  6. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
  7. Identification of alternative splicing events related to fatty liver formation in duck using full-length transcripts.
  8. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
  9. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
  10. Plastic compounds and liver diseases: Whether bisphenol A is the only culprit.